Radiation therapy plus immunotherapy for advanced kidney cancer
Treatments studied
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests a combination of targeted radiation therapy with a restart of immunotherapy for people whose kidney cancer has grown after prior immunotherapy. It aims to see if radiation can help the immune system fight the cancer again.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a type of kidney cancer called renal cell carcinoma that has spread or cannot be removed.
- Your cancer has gotten worse or you couldn't handle the side effects after at least one treatment that included an immunotherapy drug.
- You have two or more tumors in different parts of the body that can be measured.
- You are well enough to be up and about (ECOG score 0-1).
- You have not had radiation therapy before.
- You are willing to use effective birth control if you or your partner could become pregnant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether removing or burning (ablating) the main kidney tumor helps people with advanced kidney cancer who are already doing well on immunotherapy. Researchers want to see if combining local treatment with ongoing immunotherapy can improve outcomes.
This trial tests whether adding a special type of radiation to your current immunotherapy can help shrink kidney cancer tumors that have stopped responding or are stable. The goal is to see if the radiation can boost the immune system's ability to fight cancer elsewhere in the body.
This trial tests a combination of targeted therapy (axitinib) and immunotherapy (toripalimab) alongside stereotactic body radiation therapy (SBRT) for kidney cancer that has come back or spread. It may be an option if you have a limited number of metastatic tumors that can be treated with radiation.
This trial tests combining a precise type of radiation (SABR) with standard targeted therapy and immunotherapy drugs for kidney cancer that has come back or spread. The goal is to see if adding radiation improves outcomes.
This Phase 2 trial studies whether adding focused, high-precision radiation to immunotherapy helps people with advanced kidney cancer (that cannot be removed by surgery or has spread). It aims to improve cancer control by combining two treatment approaches.
This trial tests whether combining focused radiation (SBRT) with anlotinib and bimepolizumab can shrink or slow kidney cancer that has spread and cannot be surgically removed. It's designed for people with a specific type of kidney cancer who are generally healthy enough to handle these treatments.
Hear when a new Renal Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.